Orchestra BioMed Holdings, Inc.

OBIO Nasdaq CIK: 0001814114

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 150 UNION SQUARE DRIVE, NEW HOPE, PA, 18938
Mailing Address 150 UNION SQUARE DRIVE, NEW HOPE, PA, 18938
Phone 646-343-9298
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 27, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 27, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 25, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC
4 Insider stock transaction report February 13, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Achieved 25% revenue growth in 2024, reaching $12.5 million, primarily from partnership milestones.
  • Secured significant capital: $75 million from private placements, $20 million from ATM offering, and a $50 million convertible loan from Medtronic.
View Analysis

Material Events

8-K Acquisition January 12, 2026
High Impact
  • Orchestra BioMed is set to receive up to $21 million from the Vivasure acquisition.
  • A significant cash injection of $11 million is expected in 2026, with $5 million upfront and $6 million as a first milestone payment.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.